Feds Eye Partial Pretrial Ruling In Regeneron FCA Case - Law360
"naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it does not need to prove the tougher "but-for causation" standard for its ...
Read more